High HER-2 protein levels correlate with clinicopathological features in colorectal cancer

Journal of Cancer Research and Therapeutics

Volumn 12, Issue 1, 2016, Pages 323-333

  Sun, Sheng Jie ^a   Lin, Qian ^a   Sun, Qiong ^a   Li, Juan ^a   Zhang, Xing Yang ^a   Tan, Zhi Gang ^b   Song, Yan ^b   Guo, Yi Tong ^c   Li, Ying ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^c Shenyang Ninth People's Hospital   (China)

Author keywords

Clinicopathological features; colorectal cancer; disease free survival; dukes stage; HER 2; lymph node metastasis; meta analysis; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL FEATURE; CNKI DATABASE; COCHRANE LIBRARY; COLORECTAL CANCER; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; EBSCO DATABASE; EMBASE; HUMAN; LYMPH NODE METASTASIS; MEDLINE; OVERALL SURVIVAL; OVID DATABASE; PROTEIN EXPRESSION; SPRINGERLINK; SYSTEMATIC REVIEW; VIP DATABASE; WANFANG DATABASE; WEB OF SCIENCE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOSYNTHESIS; COLORECTAL TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; META ANALYSIS; PATHOLOGY; PROGNOSIS;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 84966473916     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.155977     Document Type: Article

References (59)

1. Elias D, Glehen O, Pocard M, Quenet F, Goere D, Arvieux C, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 2010;251:896-901.
2. De Simone V, Pallone F, Monteleone G, Stolfi C. Role of T17 cytokines in the control of colorectal cancer. Oncoimmunology 2013;2:e26617.
3. Fiebelkorn IC, Foxe JJ, Butler JS, Mercier MR, Snyder AC, Molholm S. Ready, set, reset: Stimulus-locked periodicity in behavioral performance demonstrates the consequences of cross-sensory phase reset. J Neurosci 2011;31:9971-81.
4. Xing XJ, Gu XH, Ma TF. Relationship of serum MMP-7 levels for colorectal cancer: A meta-analysis. Tumour Biol 2014;35:10515-22.
5. Damania D, Roy HK, Subramanian H, Weinberg DS, Rex DK, Goldberg MJ, et al. Nanocytology of rectal colonocytes to assess risk of colon cancer based on field cancerization. Cancer Res 2012;72:2720-7.
6. Qu L, Liang L, Su J, Yang Z. Inhibitory effect of upregulated DR-nm23 expression on invasion and metastasis in colorectal cancer. Eur J Cancer Prev 2013;22:512-22.
7. Tan HT, Wu W, Ng YZ, Zhang X, Yan B, Ong CW, et al. Proteomic analysis of colorectal cancer metastasis: Stathmin-1 revealed as a player in cancer cell migration and prognostic marker. J Proteome Res 2012;11:1433-45.
8. Obrocea FL, Sajin M, Marinescu EC, Stoica D. Colorectal cancer and the 7th revision of the TNM staging system: Review of changes and suggestions for uniform pathologic reporting. Rom J Morphol Embryol 2011;52:537-44.
9. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011;29:1547-55.
10. Lu Y, Jingyan G, Baorong S, Peng J, Xu Y, Cai S. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Cancer Biomark 2012;11:219-26.
11. Zong L, Chen P, Wang DX, Death decoy receptor overexpression and increased malignancy risk in colorectal cancer. World J Gastroenterol 2014;20:4440-5.
12. Pappas A, Lagoudianakis E, Seretis C, Tsiambas E, Koronakis N, Toutouzas K, et al. Clinical role of HER-2/neu expression in colorectal cancer. J BUON 2013;18:98-104.
13. Meng X, Wang R, Huang Z, Zhang J, Feng R, Xu X, et al. Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis. Cancer Sci 2014;105:818-24.
14. Vazquez-Martin A, Colomer R, Menendez JA. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 2007;43:1117-24.
15. Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-9.
16. Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
17. Chao WR, Lee MY, Lin WL, Chen CK, Lin JC, Koo CL, et al. HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer. Hum Pathol 2014;45:810-6.
18. Baric M, Kulic A, Sirotkovic-Skerlev M, Dedic Plavetic N, Vidovic M, Horvatic-Herceg G, et al. Circulating Her-2/Neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/Neu receptor coexpression. Pathol Oncol Res 2014 Nov 04 [Epub ahead of print].
19. Mamani-Cancino AD, Veloz-Martinez MG, Casasola-Busteros I, Moctezuma-Meza C, Garcia-Cebada JM. Frequency factor Her-2/neu overexpression in patients with breast cancer. Ginecol Obstet Mex 2014;82:369-76.
20. Blok EJ, Kuppen PJ, van Leeuwen JE, Sier CF. Cytoplasmic overexpression of HER2: A key factor in colorectal cancer. Clin Med Insights Oncol 2013;7:41-51.
21. Ingold Heppner B, Behrens HM, Balschun K, Haag J, Kruger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 2014;111:1977-84.
22. Chen H, Manning AK, Dupuis J. A method of moments estimator for random effect multivariate meta-analysis. Biometrics 2012;68:1278-84.
23. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 2012;31:3805-20.
24. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295:676-80.
25. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-37.
26. Wikstrom EA, Naik S, Lodha N, Cauraugh JH. Balance capabilities after lateral ankle trauma and intervention: A meta-analysis. Med Sci Sports Exerc 2009;41:1287-95.
27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
28. Wei YW. Relationship between human epidermal growth factor-2 expression and prognosis of patients with colorectal cancer. Anhui Medicine 2014;1486-7, 8.
29. Yang B, Liu B. Expression of HER-2 And Ebp1 expression in clinical significance in colorectal cancer. Chin J Med 2014;49:75-8.
30. Shin I Y, Sung NY, Lee YS, Kwon TS, Si Y, Lee YS, et al. The expression of multiple proteins as prognostic factors in colorectal cancer: Cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. Gut Liver 2014;8:13-23.
31. Liu JY, Huang GL, Zhang YT. Expression of ING4 and HER2 in colorectal cancer and their prognosis significance. Chin Gen Pract 2014:3469-72.
32. Ingold Heppner B, Behrens HM, Balschun K, Haag J, Kruger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 2014;111:1977-84.
33. Qin Y, Zhao Y, Shen X. Expression and significance of C-erbB-2 and EGFR in colorectal carcinoma. J Chengde Med Coll 2013:95-7.
34. Ying J, Xin S, Xiaoxia F. Expression and significance of vascular epithelial growth factor, epithelial growth factor receptor and human epidermal receptor-2 in colorectal carcinoma. Chin Remed Clin 2013:1263-6.
35. YJ, YL, ES G. Expression and significance of HER 2, MMP 2 and Leptin intissues of colorectal carcinoma. Anhui Med Pharm J 2012;16:479-82.
36. DL Z, YC W, Sui YX. Expression and clinical pathology relationship of c-erbB-2 protein in human colon cancer tissues. J Modern Oncol 2012:334-8.
37. Zhu Qunshan, Ping C, Wei Z. The expression of DcR3 and HER-2/neu in 60 cases with colorectal cancer and its clinical signficance. J Chin Oncol 2011:610-3.
38. YH W, C W, ZZ S. Expression and siginificance of Her-2, P53 and Ki-67 in colorectal cancer. Clin Focus 2011;1228-32:192.
39. Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 2011;11:277.
40. HM W, XJ T, Y L. Significance and expression of her-2 in colorectal cancer and clinical dendritic cell infiltration. China Cancer 2011:59-63.
41. Chen J, Li Q, Wang C, Wu J, Zhao G. Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases. Ann Surg Oncol 2010;17:1555-63.
42. Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F, et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009;9:1.
43. Baiocchi G, Lopes A, Coudry RA, Rossi BM, Soares FA, Aguiar S, et al. Erb B family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis 2009;24:1059-68.
44. WZ Z, RH L, RH X. Expression of C-erbB-2 and MRP1 in colorectal cancer. J Hebei Med Univ 2008;734-6, 8 04.
45. Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007;22:491-7.
46. Ismail HM, El-Baradie M, Moneer M, Khorshid O, Touny A. Clinico-pathological and prognostic significance of p53, Bcl-2 and Her-2/neu protein markers in colorectal cancer using tissue microarray. J Egypt Natl Canc Inst 2007;19:3-14.
47. HP G, CL Z. Relationship between expression c-erbB-2 and E-cadherin protein in colorectal cancer and clinical pathological features. Life Sci Res 2007:158-60.
48. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, et al. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J 2006;12:229-36.
49. Jesus EC, Matos D, Artigiani R, Waitzberg AF, Goldenberg A, Saad SS. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers Receptor erbb-2 and cadherins. Acta Cir Bras 2005;20:422-7.
50. X K. Relationship between expression PCNA, c-erbB2, bc1-2 and P53 protein in colorectal and clinical pathological features. Hainan Med J 2004;14-5 , 2.
51. McKay JA, Loane JF, Ross VG, Ameyaw MM, Murray GI, Cassidy J, et al. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 2002;86:568-73.
52. Lazaris AC, Theodoropoulos GE, Anastassopoulos P, Nakopoulou L, Panoussopoulos D, Papadimitriou K. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol 1995;10:661-8.
53. Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994;25:455-61.
54. Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 2011;17:1501-6.
55. Zhang DY, Zhang YH, Sun HY, Lau CP, Li GR. Epidermal growth factor receptor tyrosine kinase regulates the human inward rectifier potassium K (IR) 2.3 channel, stably expressed in HEK 293 cells. Br J Pharmacol 2011;164:1469-78.
56. Metzger B, Chambeau L, Begon DY, Faber C, Kayser J, Berchem G, et al. The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Med Genet 2011;12:144.
57. Shitara K, Yatabe Y, Matsuo K, Sugano M, Kondo C, Takahari D, et al. Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer 2013;16:261-7.
58. Campanella C, Mottolese M, Cianciulli A, Torsello A, Merola R, Sperduti I, et al. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. J Transl Med 2010;8:36.
59. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68.